CM
ACAD icon

Caption Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Caption Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.01M Buy
180,000
+80,000
+80% +$1.91M 0.02% 596
2025
Q4 		$2.67M Sell
100,000
-533,800
-84% -$12.8M 0.02% 734
2025
Q3 		$13.5M Buy
633,800
+603,800
+2,013% +$14.3M 0.11% 204
2025
Q2 		$647K Buy
+30,000
New +$558K 0.01% 1050
2024
Q4 		– Sell
-60,000
Closed -$923K – 1421
2024
Q3 		$923K Buy
60,000
+30,000
+100% +$500K 0.01% 802
2024
Q2 		$488K Sell
30,000
-432,200
-94% -$6.98M 0.01% 814
2024
Q1 		$8.55M Buy
462,200
+437,200
+1,749% +$10.8M 0.13% 199
2023
Q4 		$783K Sell
25,000
-97,500
-80% -$2.33M 0.01% 865
2023
Q3 		$2.55M Buy
122,500
+95,000
+345% +$2.58M 0.04% 519
2023
Q2 		$659K Buy
+27,500
New +$611K 0.01% 758
2022
Q4 		– Sell
-45,000
Closed -$738K – 1233
2022
Q3 		$738K Sell
45,000
-234,400
-84% -$3.8M 0.01% 968
2022
Q2 		$3.94M Buy
279,400
+57,800
+26% +$1.08M 0.05% 435
2022
Q1 		$5.37M Buy
221,600
+10,600
+5% +$257K 0.06% 400
2021
Q4 		$4.92M Buy
+211,000
New +$4.24M 0.06% 466
2021
Q3 		– Sell
-18,300
Closed -$446K – 1458
2021
Q2 		$446K Buy
+18,300
New +$413K 0.01% 1064
2021
Q1 		– Sell
-30,000
Closed -$1.6M – 996
2020
Q4 		$1.6M Buy
+30,000
New +$1.49M 0.04% 496
2020
Q1 		– Sell
-10,000
Closed -$428K – 823
2019
Q4 		$428K Hold
10,000
– – 0.01% 654
2019
Q3 		$359K Buy
+10,000
New +$303K 0.02% 530
2019
Q2 		– Sell
-35,000
Closed -$940K – 643
2019
Q1 		$940K Buy
+35,000
New +$817K 0.05% 365

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Caption Management's ACAD Position: Q1 2026 in Review

Caption Management opened a new position in Acadia Pharmaceuticals (ACAD) in Q1 2026: 120,877 shares worth $2.69M. The stake represents 0.02% of the portfolio and ranks #738 among its holdings. This is a return to the name: Caption Management previously reported a position in ACAD as recently as Q2 2025.

Caption Management first reported a position in ACAD in Q2 2018 and has held it in 16 quarters since. The position peaked at $3.24M in Q4 2020. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Caption Management held 120,877 shares of Acadia Pharmaceuticals worth $2.69M as of Q1 2026.
  • Acadia Pharmaceuticals was a new Caption Management position in Q1 2026.
  • Acadia Pharmaceuticals made up 0.02% of Caption Management's portfolio in Q1 2026, its #738 holding.
  • Caption Management first reported a position in Acadia Pharmaceuticals in Q2 2018 and has held it in 16 quarters since.
  • Caption Management's Acadia Pharmaceuticals position peaked at $3.24M in Q4 2020.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.